Evaluation of the BioVigilant® IMD-A™, A Novel Optical Spectroscopy Technology for the Continuous and Real-time Environmental Monitoring of Viable and Nonviable Particles. Part II. Case Studies in Environmental Monitoring during Aseptic Filling, Intervention Assessments, and Glove Integrity Testing in Manufacturing Isolators

References

1. 1.↵
   Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Recommendation: Isolators Used for Aseptic Processing and Sterility Testing. Pharmaceutical Inspection Co-operation Scheme. Geneva, Switzerland, 2004.
2. 2.↵
   1. Lysfjord J.,
   2. Porter M.

   Barrier Isolator History and Trends 2008 Preliminary Data. ISPE 17th Annual Barrier Isolation Technology Forum: Innovation Updates and New Case Studies. Washington, DC: June 4, 2008.
3. 3.↵
   Food and Drug Administration (FDA). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. U.S. Department of Health and Human Services, FDA: Rockville, MD, 2004. Available at http://www.fda.gov/cber/gdlns/steraseptic.pdf.
4. 4.↵
   European Commission. EU Guidelines to Good Manufacturing Practice, Annex 1. Manufacture of Sterile Medicinal Products. EudraLex, European Union: Brusselles, Belgium, 2008. Available at http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfs-en/2008_02_12_gmp_annex1.pdf.
5. 5.↵
   1. Moldenhauer J.

   1. Moldenhauer J.

   Environmental Monitoring, A Comprehensive Handbook; Moldenhauer J. Ed.; DHI Publishing: River Grove, IL and PDA: Bethesda, MD, 2007; Vol. 1 and 2.
6. 6.↵
   United States Pharmacopeia, USP 31-NF26. General Information Chapter 〈1116〉 Microbiological Evaluation of Clean Rooms and Other Controlled Environments. U.S. Pharmacopeial Convention: Rockville, MD, 2008.
7. 7.↵
   1. Prince R.

   1. Miller M. J.

   Rapid Microbiological Methods. In Microbiology in Pharmaceutical Manufacturing; Prince R. Ed.; DHI Publishing: River Grove, IL and PDA: Bethesda, MD, 2008; Vol. 2, 171– 221.

   OpenUrl
8. 8.
   1. Roszak D. B.,
   2. Colwell R. R.

   Survival strategies of bacteria in the natural environment. Microbiol. Rev. 1987, 51 ( 3), 365– 379.

   OpenUrlFREE Full Text
9. 9.
   1. Colwell R. R.,
   2. Brayton P. R.,
   3. Grimes D. J.,
   4. Roszak D. B.,
   5. Huq S. A.,
   6. Palmer L. M.

   Viable but non-culturable Vibrio cholerae and related pathogens in the environment: implications for release of genetically engineered microorganisms. Biotechnol. 1985, 3 ( 9), 817– 820.

   OpenUrl
10. 10.
    1. Colwell R. R.,
    2. Brayton P.,
    3. Herrington D.,
    4. Tall B.,
    5. Huq A.,
    6. Levine M. M.

    Viable but non-culturable Vibrio cholerae 01 revert to a cultivable state in the human intestine. World J. Microbiol. Biotechnol. 1996, 12 ( 1), 28– 31.

    OpenUrlCrossRef
11. 11.
    1. Nagarkar P. P.,
    2. Ravetkar S. D.,
    3. Watve M. G.

    Oligophilic bacteria as tools to monitor aseptic pharmaceutical production units. Appl. Environ. Microbiol. 2001, 67 ( 3), 1371– 1374.

    OpenUrlAbstract/FREE Full Text
12. 12.
    1. Williams R. H.,
    2. Ward E.,
    3. McCartney H. A.

    Methods for integrated air sampling and DNA analysis for detection of airborne fungal spores. Appl. Environ. Microbiol. 2001, 67 ( 6), 2453– 2459.

    OpenUrlAbstract/FREE Full Text
13. 13.
    1. Radosevich J. L.,
    2. Wilson W. J.,
    3. Shinn J. H.,
    4. DeSantis T. Z.,
    5. Andersen G. L.

    Development of a high-volume aerosol collection system for the identification of air-borne micro-organisms. Lett. Appl. Microbiol. 2002, 34 ( 3), 162– 167.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.
    1. Amann R. I.,
    2. Ludwig W.,
    3. Schleifer K. H.

    Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol. Rev. 1995, 59 ( 1), 143– 169.

    OpenUrlAbstract/FREE Full Text
15. 15.
    1. Hugenholtz P.,
    2. Goebel B. M.,
    3. Pace N. R.

    Impact of culture-independent studies on the emerging phylogenetic view of bacterial diversity. J. Bacteriol. 1998, 180 ( 18), 4765– 4774.

    OpenUrlFREE Full Text
16. 16.
    1. Hussong D.,
    2. Colwell R. R.,
    3. O'Brien M.,
    4. Weiss E.,
    5. Pearson A. D.,
    6. Weiner R. M.,
    7. Burge W. D.

    Viable Legionella pneumophila not detectable by culture on agar media. Bio/Technology 1987, 5, 947– 950.

    OpenUrlCrossRef
17. 17.
    1. Alvarez A. J.,
    2. Buttner M. P.,
    3. Stetzenbach L. D.

    PCR for bioaerosol monitoring: sensitivity and environmental interference Appl. Environ. Microbiol. 1995, 61 ( 10), 3639– 3644.

    OpenUrlAbstract/FREE Full Text
18. 18.
    1. Bhupathiraju V. K.,
    2. Hernandez M.,
    3. Krauter P.,
    4. Alvarez-Cohen L.

    A new direct microscopy based method for evaluating in-situ bioremediation. J. Hazard. Mater. 1999, 67 ( 3), 299– 312.

    OpenUrlPubMed
19. 19.
    1. Macher J. M.,
    2. First M. W.

    Reuter centrifugal air sampler: measurement of effective airflow rate and collection efficiency. Appl. Environ. Microbiol. 1983, 45 ( 6), 1960– 1962.

    OpenUrlAbstract/FREE Full Text
20. 20.
    1. Jensen P. A.,
    2. Todd W. F.,
    3. Davis G. N.,
    4. Scarpino P. V.

    Evaluation of eight bioaerosol samplers challenged with aerosols of free bacteria. Am. Ind. Hyg. Assoc. J. 1992, 53 ( 10), 660– 667.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.
    1. Yao M.,
    2. Mainelis G.

    Investigation of cut-off sizes and collection efficiencies of portable microbial samplers. Aerosol Sci. Technol. 2006, 40 ( 8), 595– 606.

    OpenUrl
22. 22.
    1. Yao M.,
    2. Mainelis G.

    Use of portable microbial samplers for estimating inhalation exposure to viable biological agents. J. Expo. Sci. Environ. Epidemiol. 2007, 17 ( 1), 31– 38.

    OpenUrlPubMed
23. 23.
    1. Miller M. J.

    Rapid microbiological methods and FDA's initiatives for process analytical technology and pharmaceutical cGMPs for the 21^st century: A risk based-approach. American Pharmaceutical Review 2005, 8, 104– 107.

    OpenUrl
24. 24.
    1. Miller M. J.

    Rapid microbiological methods for a new generation. Pharma. Manufac. 2006, 5, 14– 23.

    OpenUrl
25. 25.
    1. Miller M. J.

    1. Miller M. J.

    The impact of Process Analytical Technology (PAT), cGMPs for the 21st Century and Other Regulatory and Compendial Initiatives on the Implementation of Rapid Microbiological Methods. In Encyclopedia of Rapid Microbiological Methods; Miller M. J. Ed.; DHI Publishing: River Grove, IL and PDA: Bethesda, MD, 2005; Vol. 1, pp 195– 215.

    OpenUrl
26. 26.↵
    1. Miller M. J.,
    2. Lindsay H.,
    3. Valverde-Ventura R.,
    4. O'Conner M. J.

    Evaluation of the BioVigilant IMD-A, a novel optical spectroscopy technology for the continuous and real-time environmental monitoring of viable and nonviable particles. Part I. Review of the technology and comparative studies with conventional methods. PDA J. Pharm. Sci. Technol. 2009, 63 ( 3), 244– 257.

    OpenUrl
27. 27.↵
    USP 31-NF26. General Information Chapter 〈1223〉 Validation of Alternative Microbiological Methods. U.S. Pharmacopeial Convention: Rockville, MD, 2008; p 681.
28. 28.↵
    1. Miller M. J.

    1. Jiang J. P.

    Instantaneous Microbial Detection Using Optical Spectroscopy. In Encyclopedia of Rapid Microbiological Methods; Miller M. J. Ed.; DHI Publishing: River Grove, IL and PDA: Bethesda, MD, 2005, Vol. 3, pp 121– 141.

    OpenUrl
29. 29.↵
    1. Agalloco J.,
    2. Akers J. E.

    Aseptic processing: A vision of the future. Pharm. Technol. 2005, 29 ( Suppl.), 16– 23.

    OpenUrl
30. 30.↵
    1. Akers J. E.,
    2. Agalloco J. P.

    The truth about interventions in aseptic processing. Pharm. Technol. 2007, 31 ( Suppl.), 60– 76.

    OpenUrl
31. 31.↵
    1. Rauschnabel J.,
    2. Kühnle A.,
    3. Lemke K.

    Safe access using glove ports—facts and fiction. Pharm. Eng. 2005, 25 ( 6), 1– 5.

    OpenUrl
32. 32.↵
    1. Bhupathiraju V. K.,
    2. Varnau B.,
    3. Nelson J. R.,
    4. Jiang J. P.,
    5. Bolotin C.

    Evaluation of an instantaneous microbial detection system in controlled and cleanroom environments. BioPharm Int. 2007, 20, 35– 46.

    OpenUrl
33. 33.↵
    1. Tidswell E. C.,
    2. McGarvey B.

    Quantitative risk modeling in aseptic manufacture. PDA J. Pharm. Sci. Technol. 2006, 60 ( 5), 267– 283.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Akers J. E.,
    2. Agalloco J. P.

    The simplified Akers-Agalloco method for aseptic processing risk analysis. Pharm. Technol. 2006, 30 ( 7), 60– 72.

    OpenUrl
35. 35.↵
    1. Fierer N.,
    2. Liu Z.,
    3. Rodríguez-Hernández M.,
    4. Knight R.,
    5. Henn M.,
    6. Hernandez M. T.

    Short-term temporal variability in airborne bacterial and fungal populations. Appl. Environ. Microbiol. 2008, 74 ( 1), 200– 207.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Heidelberg J. F.,
    2. Shahamat M.,
    3. Levin M.,
    4. Rahman I.,
    5. Stelma G.,
    6. Grim C,
    7. Colwell R. R.

    Effect of aerosolization on culturability and viability of Gram-negative bacteria. Appl. Environ. Microbiol. 1997, 63 ( 9), 3585– 3588.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Nagarkar P. P.,
    2. Ravetkar S. D.,
    3. Watve M. G.

    Oligophilic bacteria as tools to monitor aseptic pharmaceutical production units. Appl. Environ. Microbiol. 2001, 67 ( 3), 1371– 1374.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Miller M. J.

    1. Homesley P. H.

    The RBD 3000 Rapid Bacterial Enumeration System as an Alternative to Traditional Pour Plate Enumeration. In Encyclopedia of Rapid Microbiological Methods; Miller M. J. Ed.; DHI Publishing: River Grove, IL and PDA: Bethesda, MD: 2005; Vol. 2, pp 417– 435.

    OpenUrl
39. 39.↵
    1. Miller M. J.

    1. McCormick P. J.,
    2. Norton S. E.,
    3. Costanzo S. P.

    Validation of the ScanRDI for Purified Water Testing. In Encyclopedia of Rapid Microbiological Methods; Miller M. J. Ed.; DHI Publishing: River Grove, IL and PDA: Bethesda, MD, 2005; Vol. 2, pp 317– 338.

    OpenUrl
40. 40.↵
    1. Uratani B.

    Connecting Science and Regulation. 2007 PDA 2nd Annual Global Conference on Pharmaceutical Microbiology. Bethesda, MD, October 31, 2007.
41. 41.↵
    1. Hargreaves P.

    Revised EU GMP Annex 1. 2008 PDA/EMEA Joint Conference. Budapest, Hungary, February 20, 2008.
42. 42.↵
    1. Hussong D.,
    2. Mello R.

    Alternative microbiology methods and pharmaceutical quality control. American Pharmaceutical Review 2006, 9, 62– 69.

    OpenUrl
43. 43.↵
    1. Sigwarth V.,
    2. Gessler A.,
    3. Stark A.

    Relevance of Physical Glove Integrity Testing to Microbial Contamination of Isolator Systems. ISPE 15th Annual Barrier Isolation Technology Forum, Washington, DC, June 5–6, 2006.
44. 44.↵
    1. Kampf G.,
    2. Kramer A.

    Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. Clin. Microbiol. Rev. 2004, 17 ( 4), 863– 893.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    Parenteral Drug Association. Quality Risk Management for Aseptic Processes. Technical Report #44. PDA J. Pharm. Sci. Technol. Suppl. 2008, 62 ( S-1).
46. 46.↵
    FDA. Final Report for Pharmaceutical cGMPs for the 21st Century—A Risk-based Approach. U.S. Department of Health and Human Services, FDA: Rockville, MD, 9 2004. Available at http://www.fda.gov/cder/gmp/gmp2004/CGMP%20report%20final04.pdf.
47. 47.↵
    1. Freidman R.

    Risk Management and Regulatory Considerations. PDA Risk Management and Aseptic Processing Conference, Bethesda, MD, May 16, 2008.
48. 48.↵
    1. Akers J.

    The proper role of environmental monitoring in aseptic processing. Am. Pharm. Rev. 2006, 9 ( 4), 24– 29.

    OpenUrl
49. 49.↵
    1. Katayama H.,
    2. Toda A.,
    3. Tokunaga Y.,
    4. Katoh S.

    Proposal for a new categorization of aseptic processing facilities based on risk assessment scores. PDA J. Pharm. Sci. Technol. 2008, 62 ( 4), 235– 243.

    OpenUrlAbstract/FREE Full Text